Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xilio TherapeuticsXLO +1.05%32 PS Ratio is 1.33 as of Jul. 26, 2026, which is 64% below its 10-year median of 3.74. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 930 Biotechnology companies, Xilio Therapeutics ranks better than 89.78% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Xilio Therapeutics's share price is $8.64.
Xilio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.47. Hence, Xilio Therapeutics's PS Ratio for today is 1.33.
The historical rank and industry rank for Xilio Therapeutics's PS Ratio or its related term are showing as below:
XLO'
s PS Ratio Range Over the Past 10 Years
Min: 1.19 Med: 3.74 Max: 25.01
Current: 1.33
During the past 7 years, Xilio Therapeutics's highest PS Ratio was 25.01. The lowest was 1.19. And the median was 3.74.
XLO's PS Ratio is ranked better than 89.78% of 930
companies
in the Biotechnology industry
Industry Median: 9
vs XLO: 1.33
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Xilio Therapeutics PS Ratio Related Terms
Xilio Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Xilio Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xilio Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xilio Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Xilio Therapeutics's Share Price of today is $8.64. Xilio Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.47.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Xilio Therapeutics (XLO) has a PS Ratio of 1.33 as of Jul. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Xilio Therapeutics and its competitors. This is 64% below median its historical median of 3.74. Over the past decade, Xilio Therapeutics' PS Ratio has ranged from 1.19 to 25.01. According to the industry distribution chart, Xilio Therapeutics ranks #95 out of 930 companies in the Biotechnology industry, placing it in the top 10.2%.
Is Xilio Therapeutics' PS Ratio too high?
Xilio Therapeutics' current PS Ratio of 1.33 is 64% below median its 10-year median of 3.74. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 25.01. The Biotechnology industry median PS Ratio is 9.00. Xilio Therapeutics' value of 1.33 is 85.2% below this industry median. Based on the distribution chart, Xilio Therapeutics ranks #95 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' PS Ratio compare to FLNA and BSEM?
According to the Biotechnology industry distribution chart, Xilio Therapeutics ranks #95 out of 930 companies for PS Ratio. This places Xilio Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.00. Xilio Therapeutics' value of 1.33 is 85.2% below this benchmark. Historically, Xilio Therapeutics' own PS Ratio has ranged from 1.19 to 25.01 over the past decade. While the company's 10-year median is 3.74 vs. the industry median of 9.00, Xilio Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.00, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xilio Therapeutics's current PS Ratio of 1.33 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Xilio Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xilio Therapeutics's current PS Ratio is 1.33, which is 64% below median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current PS Ratio of 1.33. The current PS Ratio is 1.33, which is 64% below median its 10-year median of 3.74 and 85.2% below the Biotechnology industry median of 9.00. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current PS Ratio is 1.33 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score
Get the complete analysis for XLO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XLO has been successfully added to your 
